A protective role of murine langerin+ cells in immune responses to cutaneous vaccination with microneedle patches

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Pulit Penaloza, Joanna A ^a   Esser, E Stein ^a   Vassilieva, Elena V ^a   Lee, Jeong Woo ^b   Taherbhai, Misha T ^a   Pollack, Brian P ^a,c   Prausnitz, Mark R ^b   Compans, Richard W ^a   Skountzou, Ioanna ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD207 PROTEIN, MOUSE; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LECTIN; MANNOSE BINDING LECTIN; MEMBRANE ANTIGEN; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DOG; FEMALE; GENE TARGETING; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRADERMAL DRUG ADMINISTRATION; MDCK CELL LINE; METABOLISM; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; TH1 CELL; TH2 CELL; VACCINATION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, SURFACE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GENE KNOCK-IN TECHNIQUES; GREEN FLUORESCENT PROTEINS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; LECTINS, C-TYPE; MADIN DARBY CANINE KIDNEY CELLS; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; TH1 CELLS; TH2 CELLS; VACCINATION; VACCINES, SUBUNIT;

EID: 84906214390     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06094     Document Type: Article

References (60)

1. Kupper, T. S. Old and new: recent innovations in vaccine biology and skin T cells. J Invest Dermatol. 132, 829-834, doi:10.1038/jid.2011.400 (2012).
2. Adalja, A. A. in Clinician's Biosecurity News, Analysis of Advances and Challenges in Clinical Biosecurity (UPCM Center for Health Security 2013 http://issuu.com/centerforbiosecurity/docs/upmc-web-2013).
3. Kim, Y. C., Park, J. H. & Prausnitz, M. R. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 64, 1547-1568, doi:10.1016/j.addr.2012.04. 005 (2012).
4. Pasparakis, M., Haase, I. & Nestle, F. O. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 14, 289-301, doi:10.1038/nri3646 (2014).
5. Sullivan, S. P. et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 16, 915-920, doi:nm.2182 [pii] 10.1038/nm.2182 (2010).
6. Koutsonanos, D. G., Compans, R. W. & Skountzou, I. Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol. 785, 121-132, doi:10.1007/978-1-4614-6217-0-13 (2013).
7. Zhu, Q. et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A. 106, 7968-7973, doi:10.1073/pnas.0812652106 (2009).
8. Quan, F. S., Kim, Y. C., Compans, R. W., Prausnitz, M. R. & Kang, S. M. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 147, 326-332, doi:10.1016/j. jconrel.2010.07.125 (2010).
9. Gill, H. S., Soderholm, J., Prausnitz, M. R. & Sallberg, M. Cutaneous vaccination using microneedles coated with hepatitis CDNAvaccine. Gene Ther. 17, 811-814, doi:10.1038/gt.2010.22 (2010).
10. Koutsonanos, D. G. et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep. 2, 357, doi:10.1038/srep00357 (2012).
11. Fernando, G. J. et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release 159, 215-221, doi:10.1016/j.jconrel.2012.01.030 (2012).
12. Matsuo, K. et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Control Release 160, 495-501, doi:10.1016/j.jconrel.2012.04.001 (2012).
13. Kommareddy, S. et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 31, 3435-3441, doi:10.1016/j.vaccine.2013.01.050 (2013).
14. Vrdoljak, A. et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 159, 34-42, doi:10.1016/j.jconrel. 2011.12.026 (2012).
15. Henri, S. et al. Disentangling the complexity of the skin dendritic cell network. Immunol Cell Biol. 88, 366-375, doi:10.1038/icb.2010.34 (2010).
16. Stoitzner, P., Tripp, C. H., Douillard, P., Saeland, S. & Romani, N. Migratory Langerhans cells in mouse lymph nodes in steady state and inflammation. J Invest Dermatol 125, 116-125, doi:10.1111/j.0022-202X.2005. 23757.x (2005). (Pubitemid 40981432)
17. Romani, N., Clausen, B. E. & Stoitzner, P. Langerhans cells and more: langerinexpressing dendritic cell subsets in the skin. Immunol Rev 234, 120-141, doi:10.1111/j.0105-2896.2009.00886.x IMR886 [pii] (2010).
18. Merad, M., Ginhoux, F. & Collin, M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 8, 935-947, doi:10.1038/nri2455 nri2455 [pii] (2008).
19. Henri, S. et al. CD2071+CD1031+dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J Exp Med. 207, 189-206, doi:10.1084/jem.20091964 jem.20091964 [pii] (2010).
20. Mahe, B. et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 129, 1156-1164, doi:10.1038/jid.2008.356 (2009).
21. Stoecklinger, A. et al. Epidermal langerhans cells are dispensable for humoral and cell-mediated immunity elicited by gene gun immunization. J Immunol. 179, 886-893, doi:179/2/886 [pii] (2007).
22. Wang, L. et al. Langerin expressing cells promote skin immune responses under defined conditions. J Immunol. 180, 4722-4727 (2008).
23. Nagao, K. et al. Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc Natl Acad Sci U S A. 106, 3312-3317, doi:10.1073/pnas.0807126106 0807126106 [pii] (2009).
24. Bachy, V. et al. Langerin negative dendritic cells promote potent CD81+T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A. 110, 3041-3046, doi:10.1073/pnas.1214449110 (2013).
25. del Pilar Martin, M. et al. Local response to microneedle-based influenza immunization in the skin. mBio 3, e00012-00012, doi:10.1128/mBio.00012-12 (2012).
26. Poulin, L. F. et al. The dermis contains langerin+dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med. 204, 3119-3131, doi:jem.20071724 [pii]10.1084/jem.20071724 (2007).
27. +dendritic cells. J Exp Med. 204, 3147-3156, doi:jem.20071966 [pii] 10.1084/jem.20071966 (2007).
28. Kissenpfennig, A. et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22, 643-654, doi:S1074-7613(05)00131-7 [pii] 10.1016/j.immuni.2005.04.004 (2005). (Pubitemid 40719199)
29. Bennett, C. L. et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol. 169, 569-576, doi:10.1083/jcb.200501071 (2005). (Pubitemid 41002850)
30. Liard, C. et al. Intradermal Immunization Triggers Epidermal Langerhans Cell Mobilization Required for CD8 T-Cell Immune Responses. J Invest Dermatol. 132, 615-625, doi:Doi 10.1038/Jid.2011.346 (2012).
31. Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 207, 974-981, doi:10.1093/infdis/jis935 (2013).
32. Constant, S. L. & Bottomly, K. Induction of Th1 and Th2 CD4+T cell responses: the alternative approaches. Annu Rev Immunol. 15, 297-322, doi:10.1146/annurev.immunol.15.1.297 (1997). (Pubitemid 27169283)
33. Purkerson, J. & Isakson, P. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J. 6, 3245-3252 (1992).
34. Seino, J. et al. Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies. Clin Exp Immunol 94, 291-296 (1993). (Pubitemid 23337829)
35. Heusser, C. H., Anderson, C. L. & Grey, H. M. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med. 145, 1316-1327 (1977). (Pubitemid 8105374)
36. Martin, R. M., Brady, J. L. & Lew, A. M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods. 212, 187-192 (1998). (Pubitemid 28288356)
37. Gerth, A. J., Lin, L. & Peng, S. L. T-bet regulates T-independent IgG2a class switching. Int Immunol 15, 937-944 (2003). (Pubitemid 36987291)
38. Weldon, W. C. et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PloS one 7, e41501, doi:10.1371/journal.pone.0041501 (2012).
39. Gerhard, W., Mozdzanowska, K., Furchner, M., Washko, G. & Maiese, K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 159, 95-103 (1997). (Pubitemid 27499862)
40. Coutelier, J. P., van der Logt, J. T., Heessen, F. W., Warnier, G. & Van Snick, J. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med. 165, 64-69 (1987). (Pubitemid 17223672)
41. Moran, T. M., Park, H., Fernandez-Sesma, A. & Schulman, J. L. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis. 180, 579-585 (1999). (Pubitemid 29411340)
42. Snapper, C. M. & Paul, W. E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944-947 (1987). (Pubitemid 17107942)
43. Calabro, K., Curtis, A., Galarneau, J. R., Krucker, T. & Bigio, I. J. Gender variations in the optical properties of skin in murine animal models. J Biomed Opt. 16, 011008, doi:10.1117/1.3525565 (2011).
44. Idoyaga, J., Suda, N., Suda, K., Park, C. G. & Steinman, R. M. Antibody to Langerin/CD207 localizes large numbers of CD8alpha1 dendritic cells to the marginal zone of mouse spleen. Proc Natl Acad Sci U S A. 106, 1524-1529, doi:10.1073/pnas.0812247106 (2009).
45. Romani, N. et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol. 351, 113-138, doi:10.1007/82-2010-118 (2012).
46. Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93, doi:10.1038/nature10766 (2012).
47. Stary, G. et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol. 186, 103-112, doi:10.4049/jimmunol.1002485 (2011).
48. King, I. L., Kroenke, M. A. & Segal, B. M. GM-CSF-dependent, CD103+dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med. 207, 953-961, doi:jem.20091844 [pii] 10.1084/jem.20091844 (2010).
49. Stoitzner, P. et al. Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci U S A. 103, 7783-7788, doi:10.1073/pnas.0509307103 (2006).
50. Liard, C. et al. Intradermal immunization triggers epidermal langerhans-cell mobilization required For CD8 T-cell immune responses. J Invest Dermatol. 131, S101-S101 (2011).
51. + dermal dendritic cells potentiate CD8+T cell responses following intradermal plasmid DNA immunization. J Immunol. 185, 3463-3471, doi:10.4049/jimmunol.1001825 (2010).
52. Steinman, R. M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319-324, doi:10.1016/j.immuni.2008.08.001 (2008).
53. Idoyaga, J. et al. Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol. 180, 3647-3650 (2008).
54. Caminschi, I., Lahoud, M. H. & Shortman, K. Enhancing immune responses by targeting antigen to DC. Eur J Immunol 39, 931-938, doi:10.1002/eji.200839035 (2009).
55. WHO/CDS/CSR/NCS. WHO Manual of Animal Influenza Diagnosis and Surveillance. Department of Communicable Disease Surveillance and Response (2002).
56. Sha, Z. & Compans, R. W. Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol 74, 4999-5005. (2000). (Pubitemid 30313838)
57. Reed, L. J. & Muench, H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497. (1938).
58. Gill, H. S. & Prausnitz, M. R. Coated microneedles for transdermal delivery. J Control Release 117, 227-237, doi:S0168-3659(06)00583-9 [pii] 10.1016/j.jconrel.2006.10.017 (2007). (Pubitemid 46161873)
59. Gill, H. S. & Prausnitz, M. R. Coating formulations for microneedles. Pharm Res 24, 1369-1380, doi:10.1007/s11095-007-9286-4 (2007). (Pubitemid 46870599)
60. Koutsonanos, D. G. et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis. 204, 582-591, doi:10.1093/infdis/jir094 (2011).